Context Therapeutics Q2 FY26 net loss widens 65% to $14.56 million year over year - CNTX News | RalliesContext Therapeutics Q2 FY26 net loss widens 65% to $14.56 million year over year
C
CNTX• Q2 FY26 results
- Context Therapeutics posted a net loss of $14.56 million for Q2 2026, widening 65% from a year earlier.
- Operating loss widened 53% to $14.97 million as research and development expense climbed 60% to $12.53 million.
- General and administrative expense rose 26% to $2.44 million, while interest income fell 54% to $418,663.
- Cash and cash equivalents totaled $43 million at June 30, 2026; it sees liquidity lasting into Q4 2027.
- Portfolio reprioritization disclosed Aug. 5, 2026, discontinuing internal CT-95 development to focus on CTIM-76 and CT-202.
KNTK
•
